⚡
The Human Energy CenterFenton LeBon, MD • nanoNAD+™
Back to Teachings Library
Nanotechnology
7 min read•Archived in NAD_Reference_Packet_Aug2026.txt & PTL DLS Report (544383-88)

nanoNAD+™: Breaking the Aggregation Barrier Through 1.92nm Dispersion

How Molecular World Health's patent-pending nanotechnology separates clumped NAD+ molecular aggregates into uniformly dispersed single molecules (1.924 nm) confirmed by Particle Technology Labs.

“The nano process has resulted in a very fine dispersion of NAD+ throughout the solution to what roughly equates to its particle size... resulting in a significant increase in NAD+ to cellular interactions.”

— Ross Grant, PhD (Leading NAD+ Neurobiologist)

Core Scientific Takeaways

  • In raw aqueous solution, conventional NAD+ clumps together into bulky molecular aggregates.
  • Particle Technology Labs (PTL) confirmed 1.924 nm hydrodynamic diameter (100% single-molecule volume).
  • High surface-area-to-volume ratio produces dramatic increases in cellular uptake and receptor kinetics.
  • Enables deep trans-follicular skin pore penetration without needle trauma.

The Unseen Problem: Molecular Aggregation

In its conventional, unrefined pharmaceutical state, raw NAD+ molecules bind together via electrostatic and hydrogen bonding, forming bulky molecular aggregates. These aggregates cannot easily penetrate skin pores or rapidly bind cellular receptors.

The Particle Technology Labs (PTL) Analysis

Under Dr. Fenton LeBon's direction, rigorous Dynamic Light Scattering (DLS) analysis was conducted by Particle Technology Labs (PTL ID: 544383-88): - Mean Particle Diameter: 1.924 nm - Peak 1 Volume: 100.0% - Peak Width: 0.4136 nm - Zetasizer Serial: MAL1017861

This demonstrates that nanoNAD+™ achieves true single-molecule dispersion, ensuring maximum bioactivity and penetration.

Related Teachings in Bioenergetics